stockrowCorcept Therapeutics Incorporated
CORT Healthcare Biotechnology
Corcept Therapeutics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $761.4 million, up 12.8% from fiscal 2024.
- Revenue
- +64.0%
- EPS
- +525.8%
- Free cash flow
- +161.0%
Quarter to September 2026, against a year earlier
Follow CORT
Alert me
Corcept Therapeutics Incorporated (CORT) Free cash flow margin
Corcept Therapeutics Incorporated's free cash flow margin over the twelve months to 30 September 2026 was 20.2%, up 1.6 percentage points from fiscal 2025 (18.6%). Over the past ten years it has ranged from 6.19% (fiscal 2015) to 45.9% (fiscal 2018); the current reading is higher than 18% of that period. That is above the Biotechnology industry median of 0.00% and above the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | 18.6% | (10.43) |
| FY2024 | 29.1% | 2.82 |
| FY2023 | 26.2% | (3.61) |
| FY2022 | 29.8% | (15.91) |
| FY2021 | 45.8% | 3.16 |
| FY2020 | 42.6% | (1.47) |
| FY2019 | 44.1% | (1.86) |
| FY2018 | 45.9% | 7.91 |
| FY2017 | 38.0% | 15.63 |
| FY2016 | 22.4% | 16.19 |
Against its own ten years
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| KRYS Krystal Biotech, Inc. compare | 66.0% |
| PTGX Protagonist Therapeutics, Inc. compare | 46.3% |
| CORT Corcept Therapeutics Incorporated | 20.2% |
| PRAX Praxis Precision Medicines, Inc. compare | 0.00% |
| ABVX Abivax SA Sponsored ADR compare | 0.00% |
| SYRE Spyre Therapeutics, Inc. compare | 0.00% |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | −11.2% |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −11.8% |
| CYTK Cytokinetics, Incorporated compare | −519.5% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on CORT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement